share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外国发行人报告
美股SEC公告 ·  08/26 08:01

Moomoo AI 已提取核心信息

NeuroSense Therapeutics Ltd., a foreign private issuer, has reported to the United States Securities and Exchange Commission (SEC) in its Form 6-K filing for August 2024. The company had previously been notified on June 21, 2024, of its non-compliance with Nasdaq's Listing Rule 5550(b), as its stockholders' equity was below the minimum requirement of $2,500,000. In response, NeuroSense Therapeutics requested a hearing with the Nasdaq Hearings Panel, which took place on August 1, 2024. During the hearing, the company presented a plan to regain compliance. On August 25, 2024, NeuroSense Therapeutics received a favorable decision from the Panel, granting an exception to remain listed on the Nasdaq Capital Market until October 31, 2024. This extension provides the company with additional time to meet the listing rule's conditions. The Form 6-K filing is also incorporated by reference into the company's registration statements on Form F-3 and Form S-8, as filed with the SEC.
NeuroSense Therapeutics Ltd., a foreign private issuer, has reported to the United States Securities and Exchange Commission (SEC) in its Form 6-K filing for August 2024. The company had previously been notified on June 21, 2024, of its non-compliance with Nasdaq's Listing Rule 5550(b), as its stockholders' equity was below the minimum requirement of $2,500,000. In response, NeuroSense Therapeutics requested a hearing with the Nasdaq Hearings Panel, which took place on August 1, 2024. During the hearing, the company presented a plan to regain compliance. On August 25, 2024, NeuroSense Therapeutics received a favorable decision from the Panel, granting an exception to remain listed on the Nasdaq Capital Market until October 31, 2024. This extension provides the company with additional time to meet the listing rule's conditions. The Form 6-K filing is also incorporated by reference into the company's registration statements on Form F-3 and Form S-8, as filed with the SEC.
NeuroSense Therapeutics Ltd.是一家外国私人发行人,已于2024年8月向美国证券交易委员会(SEC)提交了6-k表格。该公司此前于2024年6月21日收到通知,称其股东权益低于250万美元,因此不符合纳斯达克的交易所规则5550(b)。作为回应,NeuroSense Therapeutics要求与纳斯达克听证小组进行听证,该听证于2024年8月1日举行。在听证期间,公司提出了恢复合规性的计划。2024年8月25日,NeuroSense Therapeutics获得了听证小组的有利决定,允许继续在纳斯达克资本市场上市,直到2024年10月31日。这个延期为公司提供了额外的时间来满足上市规则的条件。6-k表格的提交也已被纳入公司在Form F-3和Form S-8上的注册声明中。
NeuroSense Therapeutics Ltd.是一家外国私人发行人,已于2024年8月向美国证券交易委员会(SEC)提交了6-k表格。该公司此前于2024年6月21日收到通知,称其股东权益低于250万美元,因此不符合纳斯达克的交易所规则5550(b)。作为回应,NeuroSense Therapeutics要求与纳斯达克听证小组进行听证,该听证于2024年8月1日举行。在听证期间,公司提出了恢复合规性的计划。2024年8月25日,NeuroSense Therapeutics获得了听证小组的有利决定,允许继续在纳斯达克资本市场上市,直到2024年10月31日。这个延期为公司提供了额外的时间来满足上市规则的条件。6-k表格的提交也已被纳入公司在Form F-3和Form S-8上的注册声明中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息